SARS-CoV-2 Omicron Variant in Medicinal Chemistry Research

Area of Science:

• Virology
• Drug Discovery
• Immunology

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, is complicated by the emergence of variants of concern (VOCs) like Omicron.
• Omicron (B.1.1.529) exhibits heightened transmissibility and immune evasion, including resistance to neutralizing antibodies and vaccines due to mutations in its spike protein.
• These mutations enhance ACE2 interaction and reduce therapeutic efficacy, posing a significant public health challenge.

Approach:

• This review systematically compiles identified and repurposed compounds/drugs specifically targeting the Omicron variant.
• It focuses on compounds acting against key viral targets: the spike (S) protein's interaction with ACE2, 3CLpro, RdRp, and the Nucleocapsid (N) protein.
• The compilation includes both in silico and experimental data, acknowledging the value of computational findings for future research.

Key Points:

• Omicron's spike protein has numerous mutations, facilitating immune evasion and increased infectivity by altering ACE2 binding.
• Certain compounds show broad-spectrum activity against SARS-CoV-2 variants, including Omicron, by targeting conserved regions of 3CLpro and RdRp.
• The review highlights potential therapeutic strategies and drug prototypes for combating Omicron and future SARS-CoV-2 variants.

Conclusions:

• This comprehensive review provides a valuable resource for ongoing research into SARS-CoV-2 VOCs.
• It identifies promising chemical classes of compounds that could serve as prototypes for developing novel and more effective antiviral agents against Omicron.
• The compilation aims to support global efforts in designing new therapeutic interventions against the evolving threat of SARS-CoV-2.